Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

84.36
-3.0900-3.53%
Volume:303.03K
Turnover:26.46M
Market Cap:5.76B
PE:-27.16
High:91.06
Open:88.32
Low:84.35
Close:87.45
52wk High:122.20
52wk Low:45.91
Shares:68.29M
Float Shares:55.48M
Volume Ratio:0.39
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1057
EPS(LYR):-3.1100
ROE:-90.45%
ROA:-27.51%
PB:41.42
PE(LYR):-27.13

Loading ...

Rhythm Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Yesterday

Rhythm Pharmaceuticals price target raised to $105 from $100 at H.C. Wainwright

TIPRANKS
·
Yesterday

Assessing Rhythm Pharmaceuticals (RYTM) Valuation After FDA Approval Expands IMCIVREE’s Obesity Indication

Simply Wall St.
·
Yesterday

Rhythm Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $105 From $100

THOMSON REUTERS
·
Yesterday

Rhythm Pharmaceuticals picks PANTHERx Rare as exclusive US pharmacy partner for IMCIVREE expanded indication

Reuters
·
Mar 21

Rhythm Pharmaceuticals price target raised to $149 from $139 at BofA

TIPRANKS
·
Mar 20

Palatin’s Case Strengthens as Rhythm’s FDA Approval Validates Hypothalamic Obesity Market (PTN)

TIPRANKS
·
Mar 20

BUZZ-U.S. STOCKS ON THE MOVE-Unilever, Janus, Arm Holdings

Reuters
·
Mar 20

Rhythm Pharmaceuticals Is Maintained at Market Outperform by Citizens

Dow Jones
·
Mar 20

BUZZ-U.S. STOCKS ON THE MOVE-Unilever, Gemini Space Station, FedEx

Reuters
·
Mar 20

S&P 500 Futures Decline In Premarket Trading; Super Micro Computer, Royalty Pharma Lag

Dow Jones
·
Mar 20

Wells Fargo Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Mar 20

Rhythm Pharmaceuticals Inc : Leerink Partners Raises Target Price to $142 From $136

THOMSON REUTERS
·
Mar 20

Rhythm Pharma Shares Gain 7.4% Premarket After FDA Clears Its Treatment for Brain Damage-Related Obesity

THOMSON REUTERS
·
Mar 20

BUZZ-Rhythm Pharma rises after FDA clears therapy for hypothalamic obesity

Reuters
·
Mar 20

Rhythm Pharmaceuticals trading halted, news pending

TIPRANKS
·
Mar 20

FDA approves Rhythm Pharmaceuticals' IMCIVREE for acquired hypothalamic obesity in patients aged 4 and older

Reuters
·
Mar 20

Rhythm Pharmaceuticals Announces FDA Approval of Imcivree® (Setmelanotide) for Patients With Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Mar 20

NASDAQ TRADE HALT HALT NEWS PENDING AT 06:25 PM

Reuters
·
Mar 20

Rhythm price target lowered to $100 from $110 at H.C. Wainwright

TIPRANKS
·
Mar 18